Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.

Decensi, Andrea; Sun, Zhuoxin; Guerrieri-Gonzaga, Aliana; Thürlimann, Beat; McIntosh, Christina; Tondini, Carlo; Monnier, Alain; Campone, Mario; Debled, Marc; Schönenberger, Astrid; Zaman, Khalil; Johansson, Harriet; Price, Karen N; Gelber, Richard D.; Goldhirsch, Aron; Coates, Alan S.; Aebi, Stefan (2014). Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast cancer research and treatment, 144(2), pp. 321-329. Springer 10.1007/s10549-014-2849-2

[img] Text
art_10.1007_s10549-014-2849-2.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (424kB) | Request a copy

The purpose of the study is to determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); and 2-years L, 3-years T (LT). Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after 3 (n = 150), 4 (n = 200), and 5 years (n = 74) from randomization, and 1 year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin, and bone alkaline phosphatase with T-scores were assessed. At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score, differences were significant for T versus L or TL, and L versus LT. The 5-year prevalence of spine and femur osteoporosis was the highest on TL (14.5 %, 7.1 %) then L (4.3 %, 5.1 %), LT (4.2 %, 1.4 %) and T (4 %, 0). C-telopeptide and osteocalcin were significantly associated with T-scores. While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Other Institutions > Teaching Staff, Faculty of Medicine

UniBE Contributor:

Aebi, Stefan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-6806

Publisher:

Springer

Language:

English

Submitter:

Prof. Stefan Aebi

Date Deposited:

17 Jul 2014 16:59

Last Modified:

25 Nov 2015 11:05

Publisher DOI:

10.1007/s10549-014-2849-2

PubMed ID:

24487691

BORIS DOI:

10.7892/boris.42906

URI:

https://boris.unibe.ch/id/eprint/42906

Actions (login required)

Edit item Edit item
Provide Feedback